Evidence map›Paper›PMID 37695534›Full record

ReviewHerz2023

[Cardiovascular treatment in chronic kidney disease].

Vincent Brandenburg, Turgay Saritas, Stephan H Schirmer, Kyrill Rogacev, Gunnar Henrik Heine

Abstract readReviewEnglish Abstract
PubMed Publisher
In one paragraph

Review in Herz, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Vincent BrandenburgKlinik für Kardiologie und Nephrologie, Rhein-Maas Klinikum GmbH, 52146, Würselen, Deutschland. Vincent.Brandenburg@rheinmaasklinikum.de.
Turgay SaritasKlinik für Nieren- und Hochdruckkrankheiten, Uniklinik der RWTH Aachen, Aachen, Deutschland.
Stephan H SchirmerKardiopraxis Schirmer, Kaiserslautern, Deutschland.
Kyrill RogacevKlinik für Kardiologie, Sana HANSE-Klinikum Wismar, Wismar, Deutschland.
Gunnar Henrik HeineMedizinische Klinik, AGAPLESION Markus-Krankenhaus, Frankfurt am Main, Deutschland.
Agaplesion Markus Hospital · DEKlinikum Rheine · DERWTH Aachen University · DEWismar University of Applied Sciences · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with combined cardiac and renal diseases are particularly challenging in the routine clinical practice due to the substantial risk profile for increased morbidity and mortality. As cardiorenal patients have often been underrepresented in randomized, controlled interventional trials, guideline recommendations regarding the choice of treatment are often weaker for these individuals than for cardiovascular patients without chronic kidney disease. Furthermore, there are limitations in the approval of certain medications depending on the kidney function. This review addresses some considerations in crucial treatment areas for patients with cardiovascular diseases, whose treatment is significantly influenced by concomitant chronic kidney disease.

Indexed as

Atrial FibrillationCardiovascular DiseasesRenal Insufficiency, ChronicHumansAnticoagulationAtrial fibrillationHeart failureHypercholesterolemiaHypertension

Identifiers

PMID37695534
OpenAlexW4386591938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.